A Tool to Predict Tuberculosis Drug Resistance Now Available Online
|
By LabMedica International staff writers Posted on 09 Jun 2015 |
|
![Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2015-06-09/GMS-170.jpg "Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).")
Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
A new online tool for the rapid analysis of whole genome sequence data is set to aid clinicians predict whether a particular patient's tuberculosis (TB) will be susceptible to frequently prescribed antibiotics.
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Steam Sterilizer
Hi Vac II Line
New
All-in-One Molecular System
AIO M160
Latest Microbiology News
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read more
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Blood-Based Epigenetic Signals Enable Osteosarcoma Disease Monitoring
Osteosarcoma is a rare but aggressive pediatric bone cancer where recurrence and metastasis remain difficult to detect early. Imaging-based surveillance can miss small lesions and exposes children to repeated... Read more
Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk
Epstein–Barr virus (EBV) infects more than 95% of adults worldwide, yet only a small fraction develops EBV‑associated cancers such as nasopharyngeal carcinoma. Explaining this divergence requires understanding... Read more
Hematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
Immunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more
Combined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Pathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read more
Technology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more
Industry
view channel
Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
